Drugs / LN-145-S1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03645928 | May 2019 → Feb 2026 | head and neck squamous cell carcinoma, metastatic melanoma, non-small cell lung carcinoma | Iovance Biotherapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03083873 | Jan 2017 → Aug 2022 | head and neck squamous cell carcinoma | Iovance Biotherapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LN-145-S1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03083873 ↗ |
| Modality | Cell therapy | “Multicenter, multicohort, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes...” NCT03083873 ↗ |